Department of Transportation Adds Four New Drugs to Testing Panel

by FordHarrison


Executive Summary: On November 13, 2017, the Department of Transportation (DOT) announced that it is amending its drug-testing program to require testing for synthetic opioids. The new DOT regulations now harmonize with the Department of Health and Human Services (HHS) Mandatory Guidelines for Federal Workplace Drug Testing Programs using Urine (HHS Mandatory Guidelines), published January 23, 2017.


The DOT requires urine testing for safety-sensitive transportation industry employees such as pilots, truck drivers, railroad conductors, and many others. While the DOT has discretion concerning many aspects of the regulations governing testing in the transportation industry, it must follow the HHS Mandatory Guidelines for the categories of drugs for which it requires testing. Prior to the amendment, the DOT regulations already required testing for marijuana, cocaine, amphetamines, and phencyclidine (PCP).

A Medical Review Officer (MRO) is responsible for receiving and reviewing laboratory results generated by an employer’s drug testing program and evaluating medical explanations for certain drug test results. The MRO must verify a confirmed positive test unless the employee presents a legitimate medical explanation for the presence of the drug, such as a valid prescription.

The DOT issued a Notice of Proposed Rulemaking on January 23, 2017, the same day the HHS updated its Mandatory Guidelines. After receiving comments from the public, the DOT updated the regulations to harmonize with the Mandatory Guidelines by making the following changes:

  • Addition of four semi-synthetic opioids to the DOT panel (hydrocodone, hydromorphone, oxycodone, and oxymorphone) and
  • Removal of methylenedioxyethylamphetamine (MDEA) as part of a confirmatory test from the existing drug testing panel and the addition of methylenedioxyamphetamine (MDA) as an initial test.

Adding these drugs will allow the DOT to detect a broader range of drugs being used illegally. Some common names for these semi-synthetic opioids include OxyContin®, Percodan®, Percocet®, Vicodin®, Lortab®, Norco®, Dilaudid®, and Exalgo®. Many employers with non-DOT testing programs in place already test for these drugs because of their widespread use and potentially impairing effects.

HHS monitors drug abuse trends and reviews information on new drugs of abuse, which led to the new testing requirements. Noting the national concern over the abuse of prescription opioids, the DOT stated, “[t]ransportation industries are not immune to this trend and the safety issues it raises. Consequently, the Department proposed including these substances in its testing panel not only for consistency with the HHS Mandatory Guidelines but as a response to a national problem that can affect transportation safety.”

In 2010, the DOT added a requirement for initial and confirmatory testing for MDMA, and confirmatory testing for MDA and MDEA. MDMA, MDA, and MDEA indicate the presence of the drug known as ecstasy. Initial drug tests are conducted to identify classes of drugs present in the urine. They rely on a set threshold above which a positive result is produced but do not detect lower concentrations of a drug. If a substance is detected, then additional confirmatory tests are conducted. Confirmatory testing can identify a specific drug. HHS determined that the low number of positive MDEA specimens reported did not support testing all specimens for MDEA. However, inclusion of MDA as an initial and confirmatory test substance was still warranted.

The new rules also clarify certain existing drug-testing program provisions and definitions, make technical amendments, and remove the requirement for employers and consortium/third-party administrators to submit blind specimens.

The full text of the final rule can be found here:

Employers’ Bottom Line:

The new rule goes into effect on January 1, 2018. DOT employers should modify their drug testing policies accordingly. Currently, the rules only apply to urine testing, although the HHS has issued a Notice of Proposed Rulemaking to authorize oral fluid testing.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© FordHarrison | Attorney Advertising

Written by:


FordHarrison on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.